Patents Represented by Attorney, Agent or Law Firm Debra J. Milasincic
-
Patent number: 6830898Abstract: The present invention features methods for the identification of compounds and compositions useful as antibiotics and antibacterial agents. In particular, the invention features methods for the identification of modulators of a previously unidentified target protein, termed CoaX. High-throughput assay systems are featured as well as assay kits for the identification of CoaX modulators. Also featured are coaX nucleic acid molecules and purified CoaX proteins, as well as recombinant vectors and microorganisms including the gene, coaX.Type: GrantFiled: March 20, 2001Date of Patent: December 14, 2004Assignee: OmniGene Bioproducts, Inc.Inventors: R. Rogers Yocum, Thomas A. Patterson
-
Patent number: 6825037Abstract: Recombinant transferrin, non-glycosylated recombinant transferrin, transferrin half-molecules and mutant transferrins having altered metal-binding or other properties are described. The recombinant transferrin molecules are expressed in functional form by stable eukaryotic cell lines such as baby hamster kidney cells transformed with an expression vector encoding the recombinant molecule. The recombinant transferrins can be used in metal chelation therapy to bind and clear excess toxic metals in patients suffering from metal overloads or as tissue culture medium supplements or replacements.Type: GrantFiled: November 15, 1999Date of Patent: November 30, 2004Assignees: University of Vermont, University of British ColumbiaInventors: Walter D. Funk, Ross T.A. MacGillivray, Anne B. Mason, Robert C. Woodworth
-
Patent number: 6693176Abstract: Antibodies that bind to a 40 kDa protein which is expressed on tumors, but is not expressed on normal adult hemopoietic cells are disclosed. Also disclosed are methods for production and the use of such antibodies.Type: GrantFiled: July 18, 2000Date of Patent: February 17, 2004Assignee: University of MassachusettsInventors: Kenneth L. Rock, Dancella Fernandes
-
Patent number: 6620583Abstract: The present invention features a method for identifying genes or proteins important in insulin-dependent diabetes mellitus (IDDM). The genes or proteins are useful in identifying IDDM-susceptible individuals, and in identifying and testing potential therapeutic agents for the treatment of IDDM.Type: GrantFiled: July 9, 2002Date of Patent: September 16, 2003Assignee: Boston Medical Center CorporationInventors: Barbara E. Corkey, Nicholas R. Husni
-
Patent number: 6495331Abstract: A method useful for regulating cytokine production by a hematopoietic cell by regulating an MEKK/JNKK-contingent signal transduction pathway in such a cell is disclosed. Methods of identifying compounds capable of specifically regulating an MEKK/JNKK-contingent signal transduction pathway in hematopoietic cells, a kit for identifying cytokine regulators, methods to treat diseases involving cytokine production, and cells useful in such methods are also set forth.Type: GrantFiled: May 5, 1999Date of Patent: December 17, 2002Assignee: National Jewish Center for Immunology and Respiratory MedicineInventors: Erwin W. Gelfand, Gary L. Johnson
-
Patent number: 6391602Abstract: Novel MSP-18 polypeptides, proteins, and nucleic acid molecules are disclosed. In addition to isolated, full-length MSP-18 proteins, the invention further provides isolated MSP-18 fusion proteins, antigenic peptides and anti-MSP-18 antibodies. The invention also provides MSP-18 nucleic acid molecules, recombinant expression vectors containing a nucleic acid molecule of the invention, host cells into which the expression vectors have been introduced and non-human transgenic animals in which a MSP-18 gene has been introduced or disrupted. Diagnostic, screening and therapeutic methods utilizing compositions of the invention are also provided.Type: GrantFiled: October 31, 2000Date of Patent: May 21, 2002Assignee: Millennium Pharmaceuticals, Inc.Inventor: Mehran M. Khodadoust
-
Patent number: 6312934Abstract: Isolated nucleic acid molecules encoding human MEKK proteins, and isolated MEKK proteins, are provided. The invention further provides antisense nucleic acid molecules, recombinant expression vectors containing a nucleic acid molecule of the invention, host cells into which the expression vectors have been introduced and nonhuman transgenic animals carrying a human MEKK transgene. The invention further provides human MEKK fusion proteins and anti-human MEKK antibodies. Methods of using the human MEKK proteins and nucleic acid molecules of the invention are also disclosed, including methods for detecting human MEKK activity in a biological sample, methods of modulating human MEKK activity in a cell, and methods for identifying agents that modulate the activity of human MEKK.Type: GrantFiled: March 6, 2000Date of Patent: November 6, 2001Assignee: National Jewish Center for Immunology and Respiratory MedicineInventor: Gary L. Johnson
-
Patent number: 6312921Abstract: Novel polynucleotides and the proteins encoded thereby are disclosed.Type: GrantFiled: October 20, 1998Date of Patent: November 6, 2001Assignee: Genetics Institute, Inc.Inventors: Kenneth Jacobs, John M. McCoy, Edward R. LaVallie, Lisa A. Racie, Cheryl Evans, David Merberg, Sha Mi, Maurice Treacy
-
Patent number: 6300092Abstract: Novel Lor-2 polypeptides, proteins, and nucleic acid molecules are disclosed. In addition to isolated, full-length Lor-2 proteins, the invention further provides isolated Lor-2 fusion proteins, antigenic peptides and anti-Lor-2 antibodies. The invention also provides Lor-2 nucleic acid molecules, recombinant expression vectors containing a nucleic acid molecule of the invention, host cells into which the expression vectors have been introduced and non-human transgenic animals in which a Lor-2 gene has been introduced or disrupted. Diagnostic, screening and therapeutic methods utilizing compositions of the invention are also provided.Type: GrantFiled: November 23, 1999Date of Patent: October 9, 2001Assignee: Millennium Pharmaceuticals Inc.Inventors: Mehran M. Khodadoust, Kyle J. MacBeth
-
Patent number: 6300055Abstract: The present invention features methods for diagnosing insulin-dependent diabetes mellitus (IDDM) in a test subject, for example a subject at risk of developing IDDM, which involve detecting hyper-responsive Ca2+ mobilization in cells obtained from the test subject. Hyper-responsive Ca2+ mobilization can be detected in cells contacted with a stimulatory agent, preferably in cells contacted with a potentiating agent and a stimulatory agent. Methods of the present invention include comparing Ca2+ mobilization in cells from the test subject to Ca2+ mobilization in cells from a control subject. The present invention further features kits for use in the detection of IDDM.Type: GrantFiled: August 20, 1999Date of Patent: October 9, 2001Assignee: Trustees of Boston UniversityInventors: Barbara E. Corkey, Nicholas R. Husni
-
Patent number: 6197551Abstract: Novel SPOIL-1 polypeptides, proteins, and nucleic acid molecules are disclosed. In addition to isolated, full-length SPOIL-1 proteins, the invention further provides isolated SPOIL-1 fusion proteins, antigenic peptides and anti-SPOIL-1 antibodies. The invention also provides SPOIL-1 nucleic acid molecules, recombinant expression vectors containing a nucleic acid molecule of the invention, host cells into which the expression vectors have been introduced and non-human transgenic animals in which a SPOIL-1 gene has been introduced or disrupted. Diagnostic, screening and therapeutic methods utilizing compositions of the invention are also provided.Type: GrantFiled: January 27, 1998Date of Patent: March 6, 2001Assignee: Millennium Pharmaceuticals, Inc.Inventor: Samantha J. Busfield
-
Patent number: 6194151Abstract: Novel TRL polypeptides, proteins, and nucleic acid molecules are disclosed. In addition to isolated, full-length TRL proteins, the invention further provides isolated TRL fusion proteins, antigenic peptides and anti-TRL antibodies. The invention also provides TRL nucleic acid molecules, recombinant expression vectors containing a nucleic acid molecule of the invention, host cells into which the expression vectors have been introduced and non-human transgenic animals in which a TRL gene has been introduced or disrupted. Diagnostic, screening and therapeutic methods utilizing compositions of the invention are also provided.Type: GrantFiled: March 17, 1998Date of Patent: February 27, 2001Assignee: Millenium Pharmaceuticals, Inc.Inventor: Samantha J. Busfield